| CAS No 89729-09-9 |
1,1-Cyclopropane dimethanol cyclic sulphatenull |
Inquiry |
| CAS No 90481-77-9 |
1H-Indole,3-bromo-1-[(4-methylphenyl)sulfonyl]-null |
Inquiry |
| CAS No 89031-82-3 |
Silane,(3-chloropropoxy)(1,1-dimethylethyl)dimethyl-null |
Inquiry |
| CAS No 842138-74-3 |
5-Bromoquinazolin-6-ylthioureanull |
Inquiry |
| CAS No 81822-92-6 |
2H-Benzimidazol-2-one,1-ethyl-1,3-dihydro-6-hydroxy-null |
Inquiry |
| CAS No 77557-01-8 |
2H-Benzimidazol-2-one,1,3-dihydro-1-propyl-null |
Inquiry |
| CAS No 75655-44-6 |
1H-Benzimidazole-1-propanoicacid, 2,3-dihydro-2-oxo-null |
Inquiry |
| CAS No 72798-66-4 |
2H-Benzimidazol-2-one,1,3-dihydro-1-(2-propen-1-yl)-null |
Inquiry |
| CAS No 694-98-4 |
Bicyclo[2.2.1]hept-5-en-2-onenull |
Inquiry |
| CAS No 64928-88-7 |
2H-Benzimidazol-2-one,1-(2-aminoethyl)-1,3-dihydro-null |
Inquiry |
| CAS No 6683-46-1 |
Naphthalene,1,2,3,4-tetrahydro-1,1,4,4-tetramethyl-null |
Inquiry |
| CAS No 64928-87-6 |
2H-Benzimidazol-2-one,1-(3-aminopropyl)-1,3-dihydro-null |
Inquiry |
| CAS No 58533-60-1 |
2H-Benzimidazol-2-one,5-chloro-1-ethyl-1,3-dihydro-null |
Inquiry |
| CAS No 63388-37-4 |
2H-Benzimidazol-2-one,1-[3-[4-(4-fluorobenzoyl)-1-piperidinyl]propyl]-1,3-dihydro-null |
Inquiry |
| CAS No 58533-59-8 |
2H-Benzimidazol-2-one,1-ethyl-1,3-dihydro-5-methoxy-null |
Inquiry |
| CAS No 54777-54-7 |
Pyrrolidine,2-(2-chloroethyl)-1-methyl-null |
Inquiry |
| CAS No 58533-58-7 |
2H-Benzimidazol-2-one,1-ethyl-1,3-dihydro-5-methyl-null |
Inquiry |
| CAS No 31271-90-6 |
1-(p-Toluenesulfonyl)indolenull |
Inquiry |
| CAS No 183322-18-1 |
4-Chloro-6,7-(2-methoxyethoxy)-quinazolinenull |
Inquiry |
| CAS No 2033-31-0 |
2H-Benzimidazol-2-one,6-chloro-1-ethyl-1,3-dihydro-null |
Inquiry |
| CAS No 183321-74-6 |
Erlotinibnull |
Inquiry |
| CAS No 167933-07-5 |
Flibanserinnull |
Inquiry |
| CAS No 160844-75-7 |
Ethyl 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylatenull |
Inquiry |
| CAS No 1193-55-1 |
2-Methyl-1,3-cyclohexanedionenull |
Inquiry |
| CAS No 1578-33-2 |
Furan,2-(trimethylsilyl)-null |
Inquiry |
